- Research article
- Open Access
Expression of mRNA IL-17F and sIL-17F in atopic asthma patients
BMC Research Notes volume 10, Article number: 202 (2017)
Asthma is a chronic inflammatory disorder of airway that involves many cells and elements. Chronic inflammation caused by increase Airway hyperresponsiveness that cause recurrent episodic symptoms of breathlessness, wheezing, chest tightness and coughing, especially at night or early morning. Interleukin 17F is a cytokine that plays an important role in the pathophysiology of asthma attacks. Some studies show a variety of IL-17F roles in the pathogenesis of airway inflammation due to an allergic reaction.
The study was conducted at the Prof. Dr. R. D. Kandou Manado Hospital, Indonesia. Samples were taken continuously until the number of meant samples was achieved. Blood samples were collected from 40 atopic asthmatic patients. From statistical analysis based on the hypothesis, there was positive correlation between mRNA levels of IL-17F and IL-17F in atopic asthmatic patient (p = 0.000 and r = 0.988).
According these data suggest that levels of mRNA IL-17F and IL17F might be useful parameters for the diagnosis of atopic asthma patient.
Asthma is a chronic inflammatory disorder of airways which involves many cells and elements. This chronic inflammation caused by increase airway hyperresponsiveness will manifest as recurrent episodic symptoms of breathlessness, chest tightness, wheezing and coughing, especially at night or early morning. Asthma is an important and serious public health problem in many countries in the world. Asthma can be mild and doesn’t interfere with the activity, but it can also be persistent and disturbing [1,2,3]. Atopic asthma or allergic asthma is asthma based on allergic reaction to the acquisition properties of atopy that found in family and characterized by increased total immunoglobulin E (IgE) or specific IgE. The prevalence of asthma in Indonesia ranged between 5 and 7%, in global prevalence of asthma ranging from 7 to 10%. According to data from the Center for Diseases Control and Prevention (CDC) National Asthma Control Program in United States 2010 there were 18.7 million adults suffer from Asthma and about nine people die from asthma each day [1, 2, 4, 5]. The prevalence of atopic asthma between 70 and 80% of people with asthma, and about 70–80% of people with asthma also accompanied with allergic rhinitis. The development of science and technology in the world is not entirely followed by the progress treatment for asthma, this has been shown by the data from many countries which show that number of asthma visit in emergency department, hospitalizations, morbidity and even mortality had increased . In the developed country asthma exacerbations usually is caused by a viral infection, this is different from developing countries that exacerbations are usually caused by bacteria [1, 6].
Interleukin 17F is a cytokine that plays an important role in the pathophysiology of asthma attacks. Some studies has shown variety of IL-17F roles in the pathogenesis of airway inflammation due to an allergic reaction. Interleukin 17F plays role in asthma attacks through various channels, such as affect the levels of respiratory tract neutrophil, stimulates mucus hypersecretion, respiratory hyperreactivity, airway remodeling, and resistance from steroid [7,8,9,10]. Various gene variations associated with the occurrence of asthma and asthma severity, however the genetic role of mRNA IL-17F and IL-17F has not been fully understood . This study shows that mRNA IL-17F levels and soluble IL-17F was higher in patients with asthma compared with the control group, although it has not been able to mention relationship with the severity of asthma.
Materials and methods
The study was conducted in allergy immunology clinic at Prof. Dr. R. D. Kandou Manado Hospital. After receiving approval from the hospital institutional review board, we obtained forty patients who attending allergy immunology clinic from April to October 2015. The sample selection is done by purposive sampling studies and cross-sectional study design. Informed consent was obtained from the patients.
The diagnosis of asthma is made by anamnesis history of asthma, physical examination and lung function measurements using peak expiratory flow meter based on criteria of GINA. Atopy Diagnosis is based on total serum IgE levels ≥100 IU/mL, measured using enzyme-linked immunosorbent assay (ELISA) or with a positive skin test to house dust ≥1/mites . Skin testing is done by using a 1 ml syringe with a 26 G needle sizes that are injected on the volar forearm within 1.5–2.5 cm space between allergens and scored after 15–20 min. Positive values are obtained when the ratio of allergen extract of house dust with histamine as ≥0.5 from a positive control [13, 14]. Blood samples were drawn by vein puncture from the patients at least 5 ml of whole blood. Evaluation of serum interleukin 17F blood and mRNA IL 17F samples were taken from all participants and centrifuged at 400g for 10 min. Serum samples were stored at −70 °C and then the sample transferred to laboratory for analysis. Serum levels of soluble IL-17F measured using commercially available enzyme-linked immunosorbent assay kits (Catalog no. AB100557) according to the manufacturer’s instructions with detection range from 13.72 to 10.000 pg/ml . Detection of mRNA gene IL-17F by using primary specific IL-17F forward: 5′-GTGCCAGGAGGTAGTATGAAGC-3′; IL-17F reverse: 5′-ATGTCTTCCTTCCTTG AGCATT-3′. PCR Protocol: by doubling DNA with 94 °C cycle in 3 min, repeated 38 times with 54 °C (30 s). Detection GAPDH gene by using primary forward/sense: 5′-AGTCAACGGATTTGGTCGTATT-3′; Protocol PCR: 94 °C (10 min); 32 cycle of 54 °C (30 s). Primary reverse/antisense; 5′-ATGGGTGGAATCATATTGGAAC-3′ according to Tomomi Yajima’s protocol. QRT-PCR is using the Green QRT-PCR master mix kit, one step. This protocol is optimized for the CFX Connect system, Biorad Laboratories instrument. The protocol is synced using instrument by changing coloring dilution according to the manual and following the producer company that is recommended for RT-PCR cycle program.
Passive coloring reference is put into the reaction, diluted 1:500. The solution, which contains coloring, was omitted from the light. Dilution 2x SYBR Green QRT-PCR master mix and stored on ice. Following early dilution master mix, the remaining unused part is stored in 4 °C with note, avoid solid–liquid cycle that is reduced. Reaction experiment is prepared by adding the following components. Preparing reagent mixture for reaction by using several components as follows. Reagent mixture by taking the last volume 25 μl (including RNA experiment) 12.5 μl from 2x SYBR Green QRT-PCR master mix added by 1 μl from early primary (optimized concentration) and also 0.375 μl of reference coloring mixture from the first step (optional) along with 1.0 μl from RT/Rnase mixture of block enzyme with 50 μl of total volume reaction can also be used. Reaction is mixed slowly to prevent any bubble formation (not rotated), and then mixture is distributed into reaction tubes by adding 1 μl RNA of experiment into each reaction tubes, reaction is mixed slowly to prevent any bubble formation (not rotated). Reaction is centrifuged shortly and placed into instrument and PCR program is ready to go by using Realtime PCR machine (CFX Connect system, Biorad Laboratories, Real Time PCR 96 well 0.1 ml, USA) [16, 17].
Our study was designed to have 80% power with a type I error 5% to detect significant correlation between mRNA levels of IL-17F and IL-17F in atopic asthmatic patient Mean and standard deviations for normally distributed data were calculated. Correlations were performed using Pearson’s coefficient. All statistics were performed on IBM SPSS version 20 statistical software.
A total of 40 asthma patients have range of age: 18–60 years old (43.9 ± 11.03 years) were divided into 15 male and 25 female. Hemoglobin range level 12.4–17.9 mg % (14.3 ± 1.1). Neutrophil levels range level 29.4–71.80% (52.1 ± 9.75). Total IgE range level 144–6186% (1100.98 ± 1164). mRNA IL-I7F range level 9.30–21.22 (14.18 ± 3.35) copy/μ. IL-17F range level 71.40–1904 (916.94 ± 520) pg/ml (Table 1).
Among the subject in this study the mean level of IL-17F on male subjects is higher than female subjects 1044.09 vs 840.66 pg/ml. While the mean level of IL17 mRNA level was also higher among male subject.
Correlation between serum mRNA IL-I7F with sIL-17F levels in atopic asthma patient
Forty patients were enrolled with atopic asthma. All patient has sIL-17F range level of 71.40–1904 pg/ml (916.94 ± 520) and mRNA IL-I7F range level 9.30–21.22 copy/μ (14.18 ± 3.35). Because of data mRNA IL-17F and sIL-17F were normally distributed, to evaluate correlation between mRNA levels of sIL-17F and IL-17F Pearson correlation test was used. A p value of <0.05 was considered statistically significant. The results show that mRNA levels of IL-17F and sIL-17F were significantly up regulated in asthmatic patient (p < 0.000 and r 0.988) (Table 2). Scatter plot correlation between serum IL-17F with expression of mRNA IL-17F levels in atopic asthma F and patient is shown here (Fig. 1). These data suggest that the level of mRNA IL-17F and sIL-17F might be used as parameter for diagnosis of atopic asthma.
Asthma is a disease which is usually diagnosed based on episodic symptoms and variable airway obstruction. It is also characterized by variable degrees of chronic inflammation and structural alterations in the airways [18,19,20]. This is a disease that usually affects kids and young adults at a higher frequency and is a cause of increased morbidity and mortality . Asthma is no longer regarded as a pure inflammatory disease anymore rather it’s now regarded as a disease in which involved both inflammatory and structural changes . These collective structural alterations known as airway remodeling, encompass various changes in lot of aspect of airway such as composition, content, and organization of many cellular and molecular constituents . Airway remodeling encompasses lot of aspects such as epithelial detachment, goblet cell hyperplasia, subepithelial thickening, hyperplasia and hypertrophy of airway smooth muscle, bronchial gland enlargement, angiogenesis, and alterations in the extracellular matrix components. These changes is influenced by complicated network of cytokines [23, 24]. The clarification of the modulation of this cytokine network could contribute to the understanding of asthma pathogenesis and development of new therapeutic strategies. Asthma is a chronic inflammatory disorder of the airways which is heavily driven by T cell . Both T helper (Th)2 and Th1 lymphocytes, play an important role in the pathophysiology of asthma.
The over production of T helper (Th)2 cytokines (IL-4, IL-5, IL-9 and IL-13) in the asthmatic airways is well defined, and recent studies indicate that IFN-γ which is produced by Th1 might responsible for severe airway inflammation. Recently, a separate T cell lineage, called Th17 cells or inflammatory T cells, producing IL-17A (or IL-17), has been identified. IL-17 is a 20 to 30-kD protein, the original member of the IL-17 cytokine family was first identified in 1993 and initially recognized for its similarity to a sequence belonging to the open reading frame 13 of Herpes virus saimiri. Five additional members, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F, were discovered within a short period of time since 2000 to 2002. Th17 cell was thought to play an important role in the pathophysiology of atopic asthma [8, 10, 22]. IL-17F has an important role in the recruitment of neutrophils and in asthmatic patients, studies has shown that there is an increase of expression of IL-17F in the sputum, lung, bronchoalveolar lavage fluids and peripheral blood of asthmatic patients .
Previous study discovered that activated CD4 T cell, basophils and mast cell show increase in the expression of IL-17F. These three cell is an important regulatory cell types that play important role for regulating allergic airway inflammation in bronchial asthma. While IL-17F which is produced by Th17 cell constituting independent CD4+ T cell subset . Among the IL-17 cytokine family members, IL-17F shows the highest amino acid sequence homology (50%) to IL-17A, while only 10–30% sequence identity is seen between IL-17A and the other family members . The IL-17F gene was discovered in 2001, and located on chromosome 6p12. IL17A and IL17F gene was located in same chromosome region. However, IL 17F seems to function differently from IL-17A in immune response and disease . IL-17F is derived from activated CD4+ cells, basophil and mast cell which are important regulatory cell types for allergic airway inflammation. Increased expression of IL-17F after segmental allergen challenge is seen in the bronchoalveolar lavage cells from asthmatic person. IL-17 F is expressed in both epithelium and inflammatory infiltrates [26, 27]. Immunocytochemistry showed that IL-17F positive cells in the subepithelial component and epithelium are significantly elevated in severe asthma compared with healthy and mild asthmatic subjects . Additionally, an increased expression of epithelial IL-17F was correlated with disease severity. Another recent study demonstrated that asthmatic patients have a significantly higher level of serum IL-17 F protein as compared to that of healthy subjects . This implies that IL-17F can be used as a clinical biomarker for asthma diagnosis and management. IL-17F was thought to have a role in the enhancement of allergic airway inflammation. This role was hypothesized due to finding that IL-17F has been shown to be able to induce pulmonary neutrophilia and produce an additive effect on antigen-induced allergic inflammatory response. IL-17F is also able to induce several cytokines and chemokines in bronchial epithelial cells, vein endothelial cells and fibroblast. IL-17F will affects the eosinophil, to induced several cytokines and chemokines such as IL-1β, IL-6, IL-8, GRO α, and MIP-1 β.
Another evidence for the role of sIL-17F in the pathogenesis of asthma is provided by the increase of IL-17mRNA in airways of mouse model of asthma and also in the sputum of asthmatic patients. Increase of IL-17mRNA is heavily correlated with number of neutrophils and consistent with its mRNA expression [29, 30]. Research demonstrated that in inflamed bronchi induced by allergen inhalation the IL-17F mRNA expression will be upregulated, and that sIL-17F differentially regulates bronchial influx of granulocytes induced by allergen both after single as well as after repeated allergen inhalation by sensitized mice. Rapid production of mRNA for IL-17F after allergen provocation suggested the presence of sIL-17F producing memory T cell population in inflamed airways.
This study show that mRNA levels of IL-17F and sIL-17F has significantly correlation in atopic asthmatic patient (p = 0.000 and r = 0.988). These data suggest that the levels of mRNA IL17F and sIL17F might be useful parameters for the diagnosis of atopic asthma patient.
cluster of differentiation
Center for Diseases Control and Prevention
enzyme-linked immunosorbent assay
global initiative for asthma
polymerase chain reaction
Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5:1–5.
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2015. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Pocket_2015.pdf. Accessed 5 Sept 2016.
Pettigrew HD, Chang C, Teuber SS, Gershwin ME. Clinical definitions of asthma. In: Gershwin ME, Albertson TE, editors. Bronchial asthma. 6th ed. New York: Springer; 2011. p. 3–18.
Lazarus S. Emergency treatment of asthma. N Engl J Med. 2010;363:755–64.
Centers for Disease Control and Prevention. Data from the CDC National Asthma Control Program. Atlanta: Centers for Disease Control and Prevention; 2012. http://www.cdc.gov/asthma/pdfs/investment_americas_health.pdf. Accessed 6 Oct 2015 & 5 Oct 2015.
Clark KD, Wong NW, Snashall PD. Endogenous cortisol and lung damage in a predominantly smoking population. Am J Respir Crit Care Med. 1999;159:755–9.
Ota K, Kawaguchi M, Matsukura S, Kurokawa M, Kokubu F, Fujita J, Morishima Y, Huang SK, Ishii Y, Satoh H, Hizawa N. Potential involvement of IL-17F in asthma. J Immunol Res. 2014;2014:602846. doi:10.1155/2014/602846.
Ramsey CD, Lazarus R, Camargo CA, Weiss ST, Celedon JC. Polymorphisms in interleukin 17F gene (IL17F) and asthma. Genes Immun. 2005;6:236–41.
Trevor JL, Deshane JS. Refractory asthma: mechanisms, target, and therapy. Allergy. 2014;69(7):817–27.
Tello AV, Halwani R, Rui L, Nadigel J, Bar-Or A, Mazer BD, et al. IL-17A and IL-17F expression in B lymphocytes. Int Arch Allergy Immunol. 2012;157:406–16.
Newcomb DC, Peebles RS. Th17-mediated inflammation in asthma. Curr Opin Immunol. 2013;23:755–60.
Torre ED, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone H. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy. 2014;69(2):269–72.
Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test—European standards. Clin Transl Allergy. 2013;3(3):1–10.
Haahtela T. Clinical relevance is associated with allergen specific wheal size in skin prick testing. Clin Exp Allergy. 2013;44:407–16.
Interleukin-17F ELISA kit. 2015. http://www.antibodies-online.com/kit/416867/Interleukin+17F+IL17F+ELISA/. Accessed 6 Sept 2015.
Chang Y, Nadigel J, Boulais N, Bourbeau J, Maltais F, Eidelman DH, Hamid Q. CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary diseases. Respir Res. 2011;12:43.
Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Furuya D, Hirata K, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem. 1998;44(12):2441–5.
Kawaguchi M, Fujita J, Kokubu F, Huang SK, Homma T, Matsukura S, et al. IL-17F-induced IL-11 release in bronchial epithelial cells via MSK1-CREB pathway. Am J Physiol Lung Cell Mol Physiol. 2009;296(5):804–10.
Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol. 2003;111:215–25.
Vignola AM, Kips J, Bousquet J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol. 2000;105:1041–53.
The American Academy of Allergy, Asthma & Immunology. Asthma statistics 2016. http://www.aaaai.org/about-aaaai/newsroom/asthma-statistics. Accessed 5 Sept 2016.
Alyasin S, Karimi MH, Amin R, Babaei M, Darougar S. Interleukin-17 gene expression and serum levels in children with severe asthma. Iran J Immunol. 2013;10(3):177–85.
Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol. 2005;116:477–86.
Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol. 2001;21:3–16.
Bazzi MD, Sultan MA, Tassan Al, Al Tassan N, Alanazi M, Al-Amri A, Al-Hajjaj MS, et al. Interleukin 17A and F and asthma in Saudi Arabia: gene polymorphisms and protein levels. J Investig Allergy Clin Immunol. 2011;21(7):551–5.
Oda N, Canelos PB, Essayan DM, Plunkett BA, Myers AC, Huang SK. Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response. Am J Respir Crit Care Med. 2005;171:12–8.
Park SJ, Lee YC. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res. 2010;11(78):2–11.
Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063–75.
Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wuyts A, Overbergh L, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol. 2003;28(1):42–50.
Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009;46(1):7–11. doi:10.1016/j.cyto.2008.12.024.
MH, ES, conceived and designed the study, performed statistical analysis, coordinated the data collection activities, and the laboratory examination. MH, ES, AAI, and SW participated in drafting the manuscript. All authors read and approved the final manuscript.
The authors thank to staff of Molecular Biology and Immunology Laboratory Hasanuddin University, Makassar, Indonesia and all who participated in this study.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Institutional Research Board of Prof. Dr. R. D. Kandou Manado Hospital, Indonesia (Approval PP 38/IV/Dik/2015). Patients gave written informed consent about this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Hatta, M., Surachmanto, E.E., Islam, A.A. et al. Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. BMC Res Notes 10, 202 (2017). https://doi.org/10.1186/s13104-017-2517-9
- mRNA IL-17F
- Soluble IL-17F
- Real-time PCR